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“Learn	  from	  yesterday,	  live	  for	  today,	  hope	  for	  tomorrow.	  	  
The	  important	  thing	  is	  to	  not	  stop	  questioning.”	  	  
	  
Albert	  Einstein
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ABSTRACT 
 
Acute lymphoblastic leukemia (ALL) is the most common malignancy in pediatric 
patients and is characterized by bone marrow and peripheral blood invasion from 
malignant lymphoblasts. Approximately 15% of children and 25% of adult ALL cases 
are of T-cell phenotype (T-ALL), which is associated with high risk and poorer 
prognosis. 
Interleukin-7 (IL-7) and its receptor (IL-7R) are essential for normal T-cell 
development and homeostasis. However, IL-7/IL-7R-mediated signaling may also 
partake in leukemia development, as demonstrated by the identification of IL-7Rα gain-
of-function mutations in around 9% of T-ALL patients.  
Sphingosine Kinase (SPHK) is a lipid kinase that promotes cell viability by 
phosphorylating sphingosine and thereby regulating the ceramide/sphingosine 1-
phosphate (S1P) rheostat. Cancer cells frequently display high levels of SPHK, and 
SPHK expression has been correlated with cancer patients’ outcome. Previous studies 
have shown that increased SPHK levels are correlated with increased cell viability and 
inhibition of apoptosis in chronic myeloid leukemia and acute myeloid leukemia.  
Here, we show that SPHK is an important player in IL-7-mediated signaling in T-
ALL. Initially, we demonstrated that SPHK1 expression was increased in T-ALL cells 
compared to its normal counterparts. We then hypothesized that SPHK1 could be 
involved in IL-7-mediated positive effects in T-ALL cells (both IL-7-dependent and IL-
7Rα mutant), as well as in normal T-cells. We demonstrated that IL-7 activates SPHK 
activity without significantly impacting on its expression. SPHK inhibition completely 
prevented IL-7-mediated activation of PI3K/AKT and STAT5 pathways, suggesting that 
SPHK activity is fundamental for the activation of IL-7-dependent survival pathways. In 
accordance, inhibition of SPHK decreased IL-7-dependent maintenance of 
mitochondrial membrane potential and cell viability. In addition, SPHK was necessary 
for IL-7-dependent cell cycle progression, with its inhibition inducing an arrest in 
G0/G1. Finally, SPHK inhibition downregulated CD71 surface expression and cell size 
in T-ALL. 
In summary, our study identifies SPHK1 as an essential modulator of IL-7-
mediated signaling in T-ALL, and opens new possible therapeutic approaches by using 
SPHK pharmacological inhibitors in the treatment of T-ALL patients. 
Keywords: T-Cell Acute Lymphoblastic Leukemia, Interleukine-7, Sphingosine Kinase
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INTRODUCTION 
 
1.1. An overview of T-cell development 
 
The thymus is organized into four different regions that include the subcapsular 
zone (SCZ), the cortex, the medulla, and the corticomedullary junction (CMJ, Figure 1). 
The subcapsular zone is composed by cortical thymic epithelial cells (cTECs), and the 
cortex has a mixture of cTECs, fibroblasts, and macrophages (MØ). The medulla 
contains a stromal network of dendritic cells (DCs) and medullary thymic epithelial cells 
(mTECs). The corticomedullary junction contains a dense network of endothelial cells, 
which helps the access into the thymus (1). The production of different chemokines, 
cytokines and ligands is required to interact with T-cell progenitors in development. 
One of the important cytokines is IL-7, which is produced by stromal cells in thoracic 
thymus, cervical thymus and bone marrow being required for T cell development and 
homeostasis (2). 
T-cell development occurs in the thymus. Detailed below is a summary of T-cell 
development in the mouse, where the process is better characterized. The most 
fundamental steps described here appear to be similar in humans. Thymic seeding 
progenitors (TSPs), that arrive from bone marrow (BM) (3), develop to early thymic 
progenitors (ETPs) in the thymic epithelium. The ETPs in the thymus are named CD4-
CD8- double-negative (DN) in stage 1. DN cells can be organized into four fractions 
(DN1 to DN4) (4) that are characterized by the absence of CD4 and CD8 surface 
expression and the differential expression of CD25, CD44, and CD117 according to 
development. DN1 cells (CD44+ CD25- CD117+) are heterogeneous and have potential 
to originate αβ T cells, γδ T cells, NK cells, dendritic cells, macrophages and B cells 
(3). The ETPs with high levels of CD117 are the most efficient at giving rise to T cells 
(5). Subsequently, DN1 cells leave the corticomedullary junction and migrate into the 
cortex towards the subcapsular zone, and differentiate into DN2 cells (CD25+ CD44+ 
CD117+) (1, 6). DN2 thymocytes start to rearrange TCRβ, TCRγ and TCRδ , which are 
mediated by Rag1 and Rag2 (3). When αβ and γδ T cell fate is determined, DN2 cells 
differentiate into DN3 (CD25+CD44loCD117lo) within the subcapsular zone (7). After 
that, DN3 thymocytes with low expression of CD27 (DN3a) give rise to DN3b, CD27 
high expressing cells, which leads to β-selection. This essential checkpoint requires 
TCRβ chains correctly rearranged, CD3 components and an invariant pre-TCR chain 
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(pTα)(8). The transition to DN4 (CD25-CD44-CD117-) represents the beginning of the 
return of cells towards the medulla (9). Initially, during the migration, CD8 is 
upregulated (10) (CD4 in humans), resulting in an immature intermediate single 
positive (SP) population, and TCRα recombination is also initiated (3). Then, cells 
achieve the CD4+ and CD8+ double positive stage (DP). DP cells undergo negative and 
positive selection that favors thymocytes that interact with intermediate avidity for self-
peptide-MHC complexes (presented by cTECs, DCs, and fibroblasts) and express self-
MHC restricted TCRs (11). The DP thymocytes then differentiate into the CD4 single 
positive (SP, CD4+CD8−) or CD8 SP (CD4−CD8+) lineages (12). Subsequently, SP 
cells migrate into the medulla and suffer a second negative selection, which exclude 
cells with high-affinity T-cell receptors (TCRs) for self-antigens, which avoid 
autoreactive T cell generation (13). One of the most important players responsible for 
T-cell migration is sphingosine-1-phosphate receptor 1 (S1PR1). At the end of T-cell 
maturation, S1PR expression increases at the cell surface, which allows cell migration 
from thymus to peripheral blood, where sphingosine-1- phosphate (S1P) levels are 
higher (14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of T cell migration throughout the thymus (from Koch and 
Radtke. 2011). 
	   
THE ROLE OF SPHINGOSINE KINASE 1 IN IL-7-MEDIATED SIGNALING AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
	   9	  
 
The IL-7 receptor is composed by an alpha subunit (IL-7R ) (shared by the TLSP 
receptor) and the common gamma chain (γc), which is shared among five additional 
cytokine receptors (IL-2, -4, -9, -15 and -21) (15, 16). IL-7R  is encoded by a gene on 
chromosome 5p13 and contains 8 exons. The cytokine anchorage to its receptor leads 
to receptor heterodimerization. IL-7R has no intrinsic kinase activity and so its signaling 
activation is dependent on two receptor-associated Janus kinases 1 and 3 (JAK1 and 
JAK3), which become phosphorylated and activated after IL-7 binding (17). JAK1 is 
associated with IL-7R , while JAK3 binds to γ chain (18, 19). These events precede 
the receptor tyrosine phosphorylation at residue 449 (Tyr449), which creates docking 
sites for SH2 domain proteins, such as STAT family members (20). The STAT5 and 
PI3K pathways, which are activated through JAK interaction, have been involved in 
signal transduction networks that enhance the transcription of several genes related 
with cell survival and proliferation of T-cells (21). These molecules could activate pro-
apoptotic factors or factors that are required for cell cycle progression, for instance Bcl-
2 or Cyclin D1 proteins, accordingly. On the other hand, these molecules also decrease 
the expression of some elements that control cell cycle progression, such as p27Kip1. 
(22, 23). 
IL-7Rα starts to be expressed at DN2 stage, but just at DN3 stage IL-7 signaling 
appears to outset, simultaneously with TCR  selection (24, 25). Then, IL-7Rα 
expression is downregulated at DN4 until the DP stage (26). IL-7Rα	   shutdown is 
required at the end of DN stage for DP cell differentiation, enhancing TCF-1 and LEF-1 
expression, which are transcription factors absolutely critical for T cell production (27). 
Interestingly, due to the lack of IL-7 signaling, DP thymocytes are smaller, metabolically 
inactive and pre-programmed to cell death, as indicated by the absence of BCL-2 and 
glucose transporter 1 (Glut-1) expression (26). Cell death of DP thymocytes could be 
rescued by survival signals, which are determined by thymic positive selection without 
losing self-tolerance. This means that only co-receptor tuning cells with a weak 
responsiveness to self-MHC receive other pro-survival signals from IL-7, excluding 
potential autoreactive cells (28). The TCR positive selection signals are also 
responsible for IL-7R  re-expression on immature thymocytes. Additionally, IL-7R  
appears to have another crucial function, which is to instruct for CD8 T cell lineage 
1.2. IL-7 signaling and its importance in normal T-cell development 
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differentiation (29, 30). After CD8/CD4 lineage is established, thymocytes become 
dependent on IL-7 signaling no matter their previous choice. This requirement is just 
discarded with T-cell activation or memory cell differentiation when other chain 
cytokines replace its survival role (31). 
Several studies have indicated that IL-7 is the most potent survival factor in T-
cells and has a strong effect on thymopoiesis (32, 33). In vivo, using IL-7 or IL-7R 
blocking antibodies into wild type mice leads to severe defects on thymopoiesis, 
decreasing total thymocyte number, and blocking T-cell development at DN3 stage (32, 
34). Furthermore, the IL-7 activity is not limited to thymocyte development: it is also 
responsible for the homeostasis and activity of mature T-cells (35). Lymphoid 
homeostasis refers to the preservation of the number and diversity of lymphocytes in 
an organism and this is ensured by limiting levels of IL-7 and regular contact with self-
MHC (35). Given the important role that IL-7 has on regulating hematopoiesis and 
cellular homeostasis, its expression and production are highly regulated and site-
specific. There are several transcription factors that have been associated with IL-7Rα 
expression, such as GA-binding protein (GABP), FoxO1, Runx 1 and Runx 3 (21, 36, 
37). These molecules are responsible to control IL-7R  transcription. In CD8+ SP T-
cells, the growth factor-independent-1 (Gfi-1) has been identified as a repressor of IL-
7Rα transcription, which is upregulated after IL-7 signaling activation (21). Thus, 
downregulation of IL7Rα happens upon IL-7 signaling or T-cell activation. This allows 
T-cells to achieve the maximum profit of this limiting survival cytokine, in a process that 
is named “altruistic model” (38). The suppressor of cytokine signaling (SOCS) can 
inhibit IL-7 signaling induced by multiple cytokines and growth factors (39). These 
proteins will inhibit the STAT binding by occupying its docking site, and targeting 
proteins for degradation. All together, these events enable IL-7 control, which is 
required to escape from pathway saturation, and this fine-tuning of the signal is 
essential to achieve the molecular balance for cell survival. IL-7Rα downregulation is 
also critical for normal T-cell development, allowing to select the immature thymocytes 
that correctly rearrange a functional and useful T-cell receptor (TCR). Autoimmune and 
chronic inflammatory diseases, and lymphoproliferative disorders have been correlated 
with abnormal IL-7 signaling levels (40, 41). 
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Acute lymphoblastic leukemia (ALL) is the most common cancer in pediatric 
patients, which has been organized into precursor T (or T-cell), precursor B, and B-cell 
(Burkitt) phenotypes. These groups can be sub-characterized according to recurrent 
karyotypic abnormalities. 
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignancy that 
comes up during thymocyte development, which leads to an arrest at early stages of T-
cell maturation. This disease comprises 15% of pediatric and 25% of adults’ acute 
lymphoblastic leukemia events. This pathology is clinically characterized through the 
extension of bone marrow involvement, normally with 25% or more blasts present in 
the BM, and also with the presence of blasts in the peripheral blood (42, 43). 
Regarding its clinical features, T-ALL frequently presents splenomegaly, adenopathy, 
mediastinal lymph nodes and thrombocytopenia (44). Despite BM being the 
predominant site of this disease, this malignancy tends to disseminate to all over the 
body, and could even affect the central nervous system (45, 46). 
Different genetic abnormalities in TCR gene loci have been linked to T-cell 
transformation in T-ALL development. These alterations are promoted by chromosomal 
translocations that lead to the juxtaposition of genes encoding transcriptional regulators 
close to TCR gene enhancers and promoters, which drive its expression. This 
comprises genes such as MYC, TAL1, LYL1, LMO2, TLX1, TLX3 HOXA and MYC 
(Figure 2) (47). These genetic alterations are used to classify T-ALL into subgroups. 
Other genetic abnormalities have also been described, for instance mutations and non-
random chromosomal translocations driving constitutive activation of NOTCH1, which 
altogether are reported in 31-60% of T-ALL patients (48).  
Nowadays, T-ALL treatment regimens include a combination of up to 10 different 
drugs, such as L-asparaginase, vincristine, prednisone, cyclophosphamide, 
doxorubicin, cytarabine, cyclophosphamide (49), normally composed by an intensive 
induction followed by consolidation and continuation therapy phases (49). Due to the 
fact that patients tend to suffer of central nervous system involvement, T-ALL patients 
normally receive a prophylaxis treatment for central nervous system with triple 
intrathecal medications (methrotrexate, cytosine arabinoside and hydrocortisone) (49).   
1.3. T-cell Acute Lymphoblastic Leukemia (T-ALL)  
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There are some variables that influence patient’s prognosis and have been used 
to determine high risk patients, such as age, race, white blood cell counts (WBC), 
hemoglobin, and presence of a mediastinal mass or extramedullary disease (50). 
Regarding the age at diagnosis, children with < 1 year and 10 years have worse 
prognosis. In these higher risk ages, there is an inverse correlation between age and 
prognosis (50, 51). Males and blacks have a slightly worse prognosis (52). Different 
studies have shown that WBC counts (  50 x 109/l) and central nervous system 
involvement have also worse prognosis (50). Maturational stage of the dominant clone 
has been suggested to predict patient’s outcome, with some evidence, although 
controversial, that more mature stages, as cortical T-ALL, have better prognosis. 
Children with T-ALL have worse prognosis comparing with B-ALL, with a higher 
number of high-risk patients and a higher tendency to have treatment resistance. 
Despite the comparable outcomes for T- and B-ALL high-risk patients, relapsed T-ALL 
have a disastrous prognosis with 3-year rates of event-free survival <15% (53). Over 
the past years, patient’s outcome has been improved through more efficient tools for 
risk stratification, more aggressive chemotherapies and stem cell transplantation to 
overall survival rate of 70% for children and 30-40% for adults below 60 years and 10% 
above 60 years. Despite these progresses, the high incidence of relapses remains a 
huge problem in T-ALL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Frequency of cytogenetic subtypes of childhood ALL. It shows the relative frequencies of T-
ALL (yellow) genetic subtypes. This pie chart does not include submicroscopic genetic alterations. Data 
from Pui et al (2012). 
	   
THE ROLE OF SPHINGOSINE KINASE 1 IN IL-7-MEDIATED SIGNALING AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
	   13	  
 
 
Considering that IL-7 signaling is critical for normal T cell development and cell 
survival, it is acceptable to hypothesize that survival of malignant T cells could be 
supported by IL-7. It has also been shown that pathological constitutive activation of IL-
7 pathway enhances T-ALL progression, which has been associated with its 
leukemogenic potential (54).  
AS described previously, the altered responses of leukemic cells underlie critical 
changes in gene expression. One of the most frequent mutated genes in T-ALL is 
NOTCH1, whose mutations are present in more than 50% of T-ALL patients, as 
already mentioned. IL7R  is a well-known direct target of NOTCH1, hence its 
upregulation in T-ALL with mutated NOTCH1 (48). Overexpression of IL-7 is also 
observed in thymocytes from AKR/J mice, which are highly susceptible to develop 
spontaneously thymic lymphomas (55). Besides this, several studies have 
demonstrated that a majority of T-ALL patients respond to IL-7 in vitro and IL-7 
participates in disease expansion in xenotransplantation models of human T-ALL (56, 
57). Taken together, these evidences suggest that deregulation of IL7-mediated 
signaling has a central role in T-ALL development. 
Furthermore, there are several genetic hints that indirectly discloses the 
importance of IL-7 in T-ALL, such as activating mutations in JAK1. These gain-of-
function mutations are present in 10-20% of T-ALL, and enhance constitutive activation 
of STATs, AKT and ERK proteins that are downstream of IL-7R  (58). Additionally, 
JAK3 gain-of-function mutations have also been described in 10% of a subgroup of 
high-risk (T-ALL) patients T-ALLs characterized by Early T cell phenotype (ETP-ALL) 
(59). Altogether, these studies indicate that JAK1 and JAK3 mutations have 
transforming potential in T-ALL.   
Recently, it has been shown that gain-of-function mutations in IL-7Rα are present 
in 10% of T-ALL patients. IL-7Rα mutants induce constitutive signaling independently 
not only of its ligand but also of γc and JAK3. In most cases, these mutations give rise 
to intermolecular disulfide bonds, which result from the insertion of an unpaired 
cysteine in the juxtamembrane region of IL-7Rα, a mutational hotspot region encoded 
by exon 6, leading to receptor homodimerization. This event triggers JAK/STAT5 and 
PI3K/Akt/mTOR pathways. Murine B-cell line (Ba/F3) transduced with mutant hIL-7Rα 
1.4. IL-7 signaling in T-ALL development  
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showed that the mutants promote both cell cycle progression and viability in the 
absence of growth factors (54). These findings gave a new perspective of IL-7/IL-7R-
mediated signaling in T-ALL, which could potentiate new therapeutic strategies.  
As previously described, IL-7 signaling leads to the activation of JAK/STAT and 
PI3K/Akt/mTOR pathways that enhance the transcription of several genes related with 
cell survival and proliferation (60). JAK/STAT5 is required for IL-7-dependent T-cell 
lymphomagenesis in mice (61), however its role in human T-ALL remains to be 
elucidated. PI3K activates downstream factors such as Akt and its downstream target 
mTOR. Genetic alterations in this pathway (including defects in its major negative 
regulator, the lipid phosphatase PTEN) affect 48% of T-ALL cases (62). However, 
hyperactivation of PI3K/Akt pathway is even more frequent in T-ALL due to 
posttranslational alterations, which contribute to leukemia cell maintenance (60). 
Notably, IL-7 is able to upregulate the activity of this pathway even further and T-ALL 
cells, in contrast to healthy T cell precursors, activate PI3K/Akt/mTOR pathway upon 
IL-7 stimulation in a manner that is responsible not only for cell cycle progression, but 
also for Bcl-2 upregulation and the consequent increase in cell viability (63, 64).  
These findings demonstrate an oncogenic role of the IL-7 receptor in T-ALL and 
suggest, perhaps, that the majority of T-ALL subtypes harbors an activated IL-7R 
pathway, suggesting the IL-7Rα as a potential therapeutic target in this malignancy. 
 
Sphingolipid metabolites have been identified as signaling players with a 
meaningful influence in cell fate, leading to cell proliferation/ survival or apoptosis. 
Therefore, sphingolipid synthesis and degradation pathways are highly regulated 
processes, which are determined by different players. Ceramide can be generated by 
de novo synthesis, breakdown of sphingomyelin or complex glycosphingolipids, and 
then can be deacylated into sphingosine. A key molecule in these pathways is 
sphingosine kinase (SPHK), which is responsible for the conversion of sphingosine into 
sphingosine-1-phosphate (S1P). The levels of these molecules have a role in the 
balance between cell apoptosis (sphingosine) or cell survival (S1P). This important 
switch, named sphingolipid rheostat, has been related with survival, proliferation, 
migration, angiogenesis, inflammation and differentiation (65). The biologically active 
phospholipid S1P can be reversibly modified into sphingosine by S1P phosphatases 
1.5. Sphingolipid Rheostat  
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(SPP1 and SPP2), or cleaved irreversibly into hexadecenal and phosphoetanolamide 
by S1P lyase (SPL) (66, 67). 
Commonly, S1P is generated intracellularly and then exported by ATP-binding 
cassette (ABC) super family of transporters or other mechanisms (68). S1P in the 
circulation can bind to a family of five S1P-specific cell surface G protein-coupled 
receptors (GPCRs) (S1PR1 to S1PR5) and enhances different signaling pathways, an 
event that is named inside-out signaling. For instance, PI3K/AKT, ERK1/2 or PLC are 
some of those S1P-dependent activation signaling pathways that are responsible for 
cell proliferation, migration, survival, angiogenesis, maturation, inflammation, immunity, 
chemotaxis and trafficking (65). S1P functions are not exclusively extracellular, since 
S1P also modulates histone deacetylases leading to c-fos, cell cycle regulator 
CDKN1A (p21) expression (69) and the ubiquitin ligase activity of tumor necrosis factor 
receptor-associated factor 2 (TRAF2) (70). S1P-induced TRAF2 activity and NF-kB 
activity afterwards have a pro-survival/pro-proliferative effect.  
 
S1P has been described as one of the major players in lymphocyte movement 
between BM and secondary lymphoid tissues into peripheral blood. S1P differential 
gradient between the lymphoid organs and the periphery allows lymphocyte egress.  
The first evidence of this function came from the discovery that the sphingosine 
analogue and SPHK inhibitor, Fingolimod (FTY720), leads to rapid but reversible 
lymphopenia, and lymphocytes are retained at secondary lymphoid organs 
simultaneously (14, 71). These studies also showed that S1P leads to rapid receptor 
internalization and degradation and this leads to a decrease in cell response. The 
same effect that occurs in mature lymphocytes happens in thymocytes (72). At the end 
of thymic maturation, S1PR overexpression is required to enable the exit from the 
thymus. The role of S1P in lymphocyte migration is also involved in inflammatory 
processes (73). The injured tissues increase their S1P levels, which promotes 
lymphocyte retention through S1PR1. These findings altogether demonstrate that S1P 
has an important role in hematopoiesis, however further experiments are required to 
clarify its function. 
 
 
1.6. S1P in normal hematopoiesis  
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There are two human SPHK genes, SPHK1 and SPHK2, which are located on 
chromosome 17 (17q25.2) and 19 (19q13.2) respectively, and encode SPHK1 and 
SPHK2 proteins. These are highly conserved lipid kinases which are responsible for 
S1P synthesis (74). Despite their high polypeptide sequence similarity (80%), sharing 
five highly conserved regions (C1-C5), SPHK2 presents two extra polypeptide regions 
at the N-Terminus and a central proline-rich region (75). Their differences are not only 
restricted to their structure. In fact, SPHKs display distinct development expression, 
adult tissue distribution, substrate binding, and subcellular localization, which could 
foresee distinct physiological functions (76). Although SPHK isoforms are expressed in 
all tissues in humans, SPHK1 is highest expressed in lung, spleen and leukocytes (77), 
whereas SPHK2 is increased in the kidney and liver. In addition, SPHKs are also 
differentially expressed in embryonic development (78). In mouse, SPHK1 expression 
increases earlier (E7-E11), while SPHK2 expression raises later (E15-E17) in 
embryogenesis (78). 
Different studies show that SPHK1 and SPHK2 may have antagonistic roles in 
diverse pathological conditions, such as inflammatory arthritis, kidney injury, 
lipopolysaccharide-induced injury and cancer. In the majority of the reports, SPHK1 
enhances cell survival and proliferation in different types of cancer (79-81), while there 
is no agreement respecting to SPHK2 functions. Two contrasting roles, pro-apoptotic 
and anti-apoptotic functions are suggested and SPHK subcellular position seems to be 
critical in this choice.  
Despite their different roles, genetic deletion of SPHK1 or SPHK2 has no effect in 
normal development in mice, and deletion of both SPHKs results in mice lifeless in 
utero due to several abnormalities in angiogenesis and neurogenesis (82). Altogether, 
these data indicate that SPHKs have some functional redundancy, at least in normal 
mouse development. 
 
There are three different SPHK1 isoforms (SPHK1a, SPHK1b, and SPHK1c) that 
diverge in their N-terminal domain (75). SPHK1a is secreted by human umbilical-vein 
endothelial cells and seems to contribute to increased S1P plasma levels (83). 
1.7. The Sphingosine Kinases: differences and functions 
1.8. Sphingosine kinase 1  
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SPHK1b is located at the cell membrane (84), while SPHK1c is at the Golgi and is 
present in lower levels comparing with its homologous (83). Despite these differences, 
all of them have intrinsic catalytic activity, and can be additionally activated by growth 
factors (EGF, PDGF, NGF, VEGF), cross-linking of immunoglobulin receptors, TGFB 
and TNFα, adhesion molecules (PECAM1) (85), interleukins, Ca2+ increasing agents 
and phorbol esters (74). Whereas some of these molecules lead to a rapid and 
transient activation of SPHK, promoting posttranslational modifications or changing its 
intracellular localization, others induce a biphasic mechanism, increasing initially its 
activity and then its transcription, such as EGF, estrogen, 1,25-dihydroxyvitamin D3 or 
histamine.  
Activation of SPHK1 was shown to be mediated by protein kinase C, classical 
MAPK/extracellular-signal-regulated kinases (ERKs) and PI3K/mTOR and promotes 
phosphorylation of SHPK1 at Ser225 by ERK1/2 (86). The phosphorylation of SPHK1 
increases its selectivity for phosphatidylserine at the inner leaflet of the plasma 
membrane via the side chains Thr54 and Asn89. This transient activation could be 
countered by protein phosphatase 2A (PP2A) (87). In this model, phosphorylation of 
Ser225 promotes a conformational alteration that exposes Thr54 and Asn89 and/or other 
phosphatidylserine-binding sites, which helps membrane translocation (88). Enzymatic 
activity is explained by the proximity of SPHK1 to its substrate, sphingosine, and by the 
stimulatory action of phosphatidilserine (88). Some recent evidences show that calcium 
and integrin-binding protein 1 (CIB1) facilitates active translocation of SPHK1 to the 
plasma membrane in a calcium-myristoyl dependent way and it is maintained at this 
localization through acidic phospholipids and other interactions (89). 
 
SPHK2 presents two isoforms, named SPHK2-S and SPHK2-L. The last 
mentioned isoform contains 36 additional amino acids and is the most common in 
humans (83).  
SPHK2 can also be activated by different factors, such as EGF (90), TNF-  (91), 
cross-linking of the IgE receptor Fc RI (92), phorbol esters (90) and hypoxia conditions 
(93). This lipid kinase, similarly to SPHK1, can also be activated by ERK1/2 by 
phosphorylation at Ser351 and Thr578 (94). 
1.9. Sphingosine kinase 2 
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SPHK2 displays nuclear localization (NLS) and export (NES) signals (95, 96). 
When SPHK2 is located in the nucleus, it prevents DNA synthesis (96) and regulates 
epigenetic modifications modulating HDAC1/2 (97). Increased acetylation of H3, H4 
and H2B leads to increased expression of cyclin-dependent kinase inhibitor (CDKN1A) 
and the transcriptional regulator FOS (69). Besides this, SPHK2 localized at the 
nucleus seems to be related with contact inhibition responses, which decrease cell 
proliferation. On the other hand, it has been shown that SPHK2 is located at 
endoplasmic reticulum under stress conditions, which is associated with increased 
levels of pro-apoptotic ceramide (76). SPHK2 positioning at mitochondrial membrane 
also leads to cell apoptosis via S1P, BAK and cytochrome c release (97). By contrast, 
SPHK2 placed at the plasma membrane promotes cell proliferation. Interestingly, it has 
been shown that SPHK1 artificially targeted to the ER or nucleus leads to apoptosis 
(76). These findings indicate the major involvement of the SPHK location in its 
functions.  
 
Different studies have demonstrated that SPHK1 displays oncogenic features. 
Normal NIH3T3 fibroblasts that have upregulated SPHK1 show tumorigenic features, 
as indicated by colony growth in soft agar (98). 
Overexpression of SPHK1 has been shown in different types of cancer, such as 
breast, lung, ovary, stomach, uterus, kidney, where its levels are 2-fold higher 
comparing with normal tissue (99, 100). Furthermore, SPHK1 upregulation has also 
been associated with poor prognosis in gastric, breast, brain and lung cancer patients 
(81, 101, 102). Moreover, SPHK inhibitors significantly decrease tumor growth in mice 
(103, 104) and cells lacking SPHK1 become more sensitive to chemotherapeutic 
treatments (105). 
Several studies have demonstrated the proliferation potential of SPHK1 in 
hematological malignancies. SPHK1 activation is promoted by interleukin-6 in multiple 
myeloma cells (106), and PDGF seems to induce a similar effect in T-cell large 
granular lymphocytic leukemia (T-LGL) (107). Interesting, protein kinase C (PKC), 
classical MAPK/ ERKs and PI3K/mTOR are some of the signaling pathways that are 
implicated in SPHK1 activation and which have been shown to be deregulated in 
leukemia (86). In erythroleukemia, SPHK1 overexpression is required to promote 
1.10. Sphingosine kinase role in malignant development  
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leukemia development and progression (108), and BCR/ABL1 increased SPHK1 
expression in CML (109). Furthermore, S1P pro-survival signals avoid cytochrome c 
and Smac/Diablo release in leukemia cell lines, upregulating anti-apoptotic molecules 
such as Mcl-1 in chronic myeloid leukemia and multiple myelomas (110). Inhibition of 
SPHK1 activity in leukemia cells, for instance in CML (111) and T-LGL (112), promotes 
cell death.  
As described before, while SPHK1 role in cancer is well established, SPHK2 
appears to have a dual role in cancer development and progression. Some studies 
have demonstrated that SPHK2 has also a similar function to SPHK1. In MCF7 human 
breast cancer cells, SPHK2 knockdown prevents growth of xenografted tumors (113). 
Further, some studies showed that chemical inhibition of SPHK2 reduced proliferation 
and induced autophagy cell death in kidney, prostate and breast cell lines (114, 115).  
Although the effects of SPHK2 in hematological malignancies are much less 
known, the importance of SPHK2 starts to emerge. Recently, Wallington-Beddoe et al. 
showed that SPHK2 has a role in B-ALL, through the expression of the oncogene MYC 
and that SPHK2 activity signature is increased in ALL patients (116).  
Together, these studies elucidate the critical involvement of SPHK in malignant 
development, and consequently SPHK arises as an evident therapeutic target. There 
are several pre-clinical studies using FTY720 inhibitor in disseminated lymphoma 
(117), CML (118), murine cell line models of AML with KIT mutations (119), and also in 
rat models of NK leukemia (119). Moreover, in mice engrafted with human AML U937 
cell line, treatment with a SPHK1 inhibitor reduces tumor growth (120), and in a human 
xenograft model of Ph+ ALL, a SPHK2 inhibitor has anti-leukemic potential, which 
cooperates with Imatinib (116). Nonetheless, the effects of SPHK1 and SPHK2 
inhibitors on hematological malignancies are still poorly explored. 
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OBJECTIVES 
Taken all of the findings summarized above together, we hypothesized that 
SPHK1 and/or 2 (hereby jointly reffered to as SPHK) may be involved in T-ALL and 
particularly in IL-7-mediated signaling in this malignancy. Hence, this research project 
intended to investigate the importance of SPHK in normal and mutant IL-7Rα signaling 
in T-ALL.  
To accomplish our main goal, we defined some critical questions:  
1. What are the levels of SPHK expression? Are they increased in T-ALL 
patients? 
2. Does IL-7 regulate SPHK expression and/or activity? 
3. Is SPHK involved in IL-7 mediated signaling in T-ALL cells? 
4. What are the effects of SPHK inhibition on IL-7-mediated cell viability, 
cell cycle, activity and proliferation of T-ALL cells? 
In order to address these questions, we used the following cell lines:  D1, a 
murine IL-7-dependent thymocyte-like cell line; TAIL7, a human IL-7-dependent 
primary-like T-ALL cell line; DND4.1, a human IL-7Rα mutant T-ALL cell line.  These 
cell lines were cultured with a SPHK pan inhibitor, SKI-II. Although we performed some 
analyses discriminating between SPHK1 and 2, the functional studies we performed so 
far made use only of SKI-II. As such, we opted to name SPHK1 and SPHK2 jointly as 
SPHK in most parts of the present thesis, although we are aware that not necessarily 
the two are involved in IL-7-mediated signaling.  
We speculated that SPHK may partake in and drive IL-7-mediated signaling 
pathways, by being required for full activation of IL-7 downstream elements (Figure 3). 
If confirmed, this could constitute the first step towards the characterization of SPHK as 
a key molecule in IL-7-mediated signaling and a new potential therapeutic target in T-
ALL. 
 
 
 
 
 
 
 
 
 
	   
THE ROLE OF SPHINGOSINE KINASE 1 IN IL-7-MEDIATED SIGNALING AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
	   21	  
 
 
 
Figure 3: Proposed model for SPHK role in IL-7-mediated signaling. The dashed arrows represent our 
hypothesis, as SPHK could partake in IL-7-mediated signaling pathways by being required to the full 
activation of IL-7 downstream elements.  
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MATERIALS AND METHODS 
 
3.1. Reagents and Antibodies  
SKI-II, 2-(p-Hydroxyanilino)-4-(p-chlorophenyl) thiazole, which is a SPHK pan-
inhibitor, was synthesized by Calbiochem® (Merck Millipore). 
The following were used as primary antibodies: p27kip1 (BD Transduction 
Laboratories), phospho-JAK3 (Y980), JAK3, JAK1, STAT5, SPHK1, Actin, Caspase-3, 
(Santa Cruz Biotechnology), phospho-STAT5A/B (Y694/Y699; Upstate Biotechnology), 
and phospho-JAK1 (Y1022/1023), phospho-Akt (S473), phospho-Erk1/2 (T202/Y204), 
Akt, Erk1/2, phospho-PTEN (S380) and PTEN (Cell Signaling Technology). 
Immunodetection was performed with horseradish peroxidase–conjugated anti–mouse 
IgG, anti–rabbit IgG or anti–goat IgG (Promega). 
 
3.2. Cell Culture 
TAIL7, a human T-ALL IL-7 dependent primary-like cell line, was grown in the 
presence of 10ng/ml of human IL-7, in RPMI medium (Gibco) supplemented with 5% of 
fetal bovine serum (FBS) (PAA Laboratories GmbH), at a concentration of 2 × 
106 cells/ml. The human T-ALL cell line DND-4.1 was cultured in RPMI 10% of FBS 
(Biowest) at a concentration of 0,5× 106 cells/ml. The murine IL-7 dependent cell line 
D1 was grown in the presence of 50 ng/ml of human IL-7 in RPMI with 10% of FBS 
(PAA), at a concentration of 1 × 106 cells/ml. The human T-ALL cell line Jurkat was 
cultured in RPMI 10% of FBS (PAA) at 0,5× 106 cells/ml.  
 
3.3. In Vitro Culture 
TAIL7 cells were plated in 6-well plates or 96-well plates at 2×106 cells/ml at 37°C 
with 5% CO2. Serum and IL-7 starved TAIL7 cells for 24h were incubated in RPMI 5% 
FBS (control medium) with 20 ng/ml of IL-7, SKI-II or both. Following, cells were 
harvested and processed for western blot or FACS analysis, accordingly.  
D1 cells were plated in 6-well plates or 96-well plates at 1×106 cells/ml at 37°C 
with 5% CO2 in RPMI 10% FBS (control medium) in the presence of 50 ng/ml IL-7 and 
SKI-II, or both. D1 cells were starved in RPMI without FBS and IL-7 for 2h prior to any 
stimulation. 
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DND-4.1 cells were plated in 6-well plates or 96-well plates at 0,5×106 cells/ml at 
37°C with 5% CO2 in RPMI 10% FBS (control medium) with or without SKI-II. 
 
3.4. Protein Extraction 
Collected cells were centrifuged at 3500 rpm for 5 minutes at 4ºC in order to 
obtain a cell pellet. Cell pellet was ressuspended in lysis buffer (50mM Tris-Base; 
150mM NaCl; 5mM EDTA; 1mM NaOVa; 10mM NaF; 10mM NaPyrophosphate; 1% 
NP-40, supplemented with protease inhibitor cocktail Complete Mini (Roche) and 
protease inhibitor AEBSF (1mM)). The extracts were centrifuged at 13000 rpm for 15 
minutes at 4°C and the supernatants were collected. Total protein quantification was 
performed by Bradford assay (absorbance at 595nm). Protein extracts were 
ressuspended in Laemmli buffer and denatured at 95 °C for 5 minutes. 
 
3.5. Western Blot 
Samples were separated by SDS-PAGE (12 or 14% of acrylamide gel) and 
transferred onto a nitrocellulose membrane. Precision Plus ProteinTM (Bio-Rad) 
molecular weight standards were used as reference. Protein transference was carried 
out using conventional transference system (90 min, 400mA). Membranes were 
submerged in Ponceau S solution in order to evaluate the protein content. The 
membranes were then blocked (3% skimmed milk, TBS-T buffer) and then incubated 
with primary antibody diluted in TBS-T (in pre-established dilutions and antibody 
specific) overnight at 4°C under constant agitation. After washing the membranes for 
25 min in TBS-T (in a total of three washing steps), the membranes were incubated 
with the respective secondary antibody diluted (1:5000) in a 3% milk/TBS-T buffer 
blocking solution and incubated for 1 hour at room temperature under constant 
agitation. Chemiluminescence detection was carried out using the Pierce ECL Plus 
Western Blotting Substrate (Thermo Fisher Sientific Inc.). Membranes were revealed 
using the Curix60 (AGFA HealthCare). 
 
3.6. Membrane Stripping 
In order to perform a new blot of the membrane, the antibodies were removed by 
stripping process. The membranes were incubated in the stripping solution (Tris-HCl, 
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β-mercaptoethanol (100mM), 10% SDS, pH 6.7) for 30 minutes with mild agitation at 
56ºC. Finally, the membrane was washed in water and then in TBS-T. Primary and 
secondary antibody solutions were then applied as described before. 
 
3.7. Quantitative Real-Time PCR 
The mRNA expression of SPHK1 and 2 was quantified using a 7500 Fast or ViiA 
7 Real-Time PCR System (Applied Biosystems). The following primer sequences were 
used, human SPHK1 forward: CTT GCA GCT CTT CCG GAG TC and reverse: CAC 
GCT GAT GCT CAC TGA GC; mouse SPHK1 forward: TGT GAA CCA CTA TGC TGG 
GTA and reverse: CAG CCC AGA AGC AGT GTG, 18 S rRNA forward: GGA GAG 
GGA GCC TGA GAA ACG and reverse: CGC GGC TGC TGG CAC CAG ACT T,  
human SPHK2 forward: CTG TCT GCT CCG AGG ACT GC  and reverse: GAC CCC 
CAA AGG GAT TGA CCA AT; mouse SPHK2 forward: GGA GACG GGC TGC TTT 
ACG AG and reverse: (tudo o que está sublinhado não está a preto, está a cinza. 
Confere) GATCCACAGGGGAGGACACC. 
 
3.8. Analysis of cell viability, size and CD71 surface expression 
Cell viability was determined by double-staining with APC-conjugated Annexin V 
(eBioscience) and 7-AAD (BD Biosciences) followed by flow cytometric analysis on a 
LSRFortessa flow cytometer (BD Biosciences). Briefly, cells were washed with PBS 
and ressuspended in 100 µL of binding buffer with Annexin V and 7-AAD. After 15 
minutes of incubation at room temperature in the dark, 100 µL of binding buffer were 
added and the samples were acquired. Fully viable cells were identified as the Annexin 
V and 7-AAD double-negative populations.   
Cell size was assessed by analysis of SSC versus FSC flow cytometry plots 
gated on the live cell population. Samples were analyzed using LSRFortessa flow 
cytometer (BD Biosciences) and FACSDiva software (BD Biosciences). Results were 
analyzed by FlowJo software (Tree Star). 
Transferrin receptor (CD71) surface expression was analyzed by flow cytometry 
using FITC-conjugated anti-CD71 (eBioscience) antibody. Results were expressed as 
the specific mean intensity of fluorescence (MIF). 
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3.9. Cell Cycle Analysis 
Cells were harvested, washed with PBS and fixed in 80% ethanol at -20ºC. Cells 
were ressuspended in PBS containing 50 ug/ml RNase A and incubated at 37ºC for 30 
minutes. Samples were labeled with 100ul/ml propidium iodide (PI) and were analyzed 
using a FACSCalibur flow cytometer (BD Biosciences). Cell cycle modeling was 
performed using ModfitTM LT software (Verity Software House Biosciences).  
 
3.10. Assessment of Mitochondrial Membrane Potential (Δψm) 
Cells were harvested and stained in culture medium with TMRE (Sigma-Aldrich) 
to a final concentration of 100 nM, and incubated for 15 min at 37°C. Cells were 
analyzed for TMRE intensity by flow cytometry. Samples were analyzed using 
LSRFortessa flow cytometer (BD Biosciences) and FACSDiva software (BD 
Biosciences). Results were analyzed by FlowJo software (Tree Star). 
 
3.11. Proliferation Assays  
Cells were cultured in triplicates in flat bottom 96-well plates at the normal cell 
culture density and conditions as indicated previously. IL-7 cytokine and/or SPHK 
inhibitor were added in the experimental conditions mentioned above. Cells were 
incubated with [3H] labelled thymidine at the concentration of 1 Ci/well for 16 h (TAIL7 
cell line) or 8h (remaining cell lines) before harvest. DNA synthesis, as measured by 
[3H] thymidine incorporation, was assessed using a scintillation counter (Perkin Elmer). 
Average and standard deviation of triplicates were calculated. 
 
3.12. Sphingosine Kinase Activity Assay 
The SPHK Activity was measured through a commercial kit from Echelon Inc. 
(SPHK Activity Assay). This is a based luminescent assay that measures SPHK 
activity by detecting the consumption of ATP transformation of sphingosine into S1P. 
The experimental conditions were conducted as described previously. Total cell 
lysates were collected in lysis buffer (described previously in western blot section) and 
supplemented with Triton-X 100 (0,1%) or KCL (1M) in order to discriminate SPHK1 
and SPHK2 activity, respectively. The assay was performed accordingly to 
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manufacturer instructions. The luminescence signal was detected after one hour of 
incubation with the microplate reader Infinite M20 (Tecan). The integration time was 
set to 1000ms per well. 
 
3.13. Statistical analysis  
Statistical computations were performed with GraphPad Prism version 5.0 for 
Windows (GraphPad Software). In what concerns the differences among groups, it 
was performed ANOVA, t-Student or Mann-Whitney statistical tests, as appropriate. 
Differences among groups were considered statistically significant at p ≤0,05 (95% 
confidence interval). 
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RESULTS  
 
4.1. Sphingosine Kinase Expression in T-ALL 
Given the existing evidence that SPHK is upregulated in other leukemias, we 
analyzed gene expression of SPHK1 and SPHK2 in T-ALL patients and normal 
thymocytes by qRT-PCR. SPHK1, but not SPHK2, transcript levels were increased in 
T-ALL samples (p = 0.0462) comparing with normal thymocytes (Figure 4A). We also 
analysed a publicly available dataset (GSE7186) for SPHK expression, that 
corroborated our initial analysis and showed that SPHK1 expression was higher in T-
ALL (p = 0.0439) as compared to normal bone marrow samples (Figure 4A and 4B). 
In order to determine the effect of IL-7 stimulation on SPHK1 gene expression, 
we incubated TAIL7 and D1 cell lines in the presence or absence of IL-7. We found 
that IL-7 did not significantly affect SPHK1 expression (Figure 4C). Similar results were 
obtained for SPHK2 expression with or without IL-7 stimulation (data not shown). The 
effect of IL-7 on SPHK activity was then evaluated in TAIL7 and D1 cell lines. In 
contrast to the expression levels, IL-7 stimulation in TAIL7 cells clearly upregulated 
total SPHK activity (p = 0.0393, Figure 4D). In D1 cells, we observed that SPHK1 
activity was higher than SPHK2 activity and that IL-7 withdrawal decreased the activity 
of both enzymes (p = 0.0305 and p = 0.0042, Figure 4D). 
Together, these results show that SPHK1 is significantly more expressed in T-
ALL samples compared to their normal counterparts and that IL-7 stimulation positively 
regulates SPHK kinase activity without significantly affecting SPHK transcript levels. 
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Figure 4: IL-7 stimulation positively regulates SPHK mRNA levels and activity. (A) Peripheral blood 
or bone marrow samples were collected from T-ALL patients at the time of diagnosis and total RNA was 
extracted. Statistical analysis was performed using Mann-Whitney test from triplicates. Relative expression 
of SPHK1 was significantly different between groups (p = 0.0462), whereas no statistical differences in 
SPHK2 expression were observed. (B) A publicly available dataset of gene expression (GSE7186) was 
manual analysed. Statistical analysis was performed using Mann-Whitney test (p = 0.0439). (C) TAIL7 
cells were starved for 24h and cells were collected after 16 and 24 hours of incubation in the presence or 
absence of 20ng/ml of IL-7. D1 cells were starved for 2h and cells were collected after 8 and 16 hours of 
incubation with presence or absence of 50 ng/ml of IL-7. Then RNA was extracted with subsequent cDNA 
production and qRT-PCR analysis. The observed differences between IL-7 presence and absence were 
not statistically significant. (D) TAIL7 cells were starved for 24h and protein extracts were collected after 24 
hours of incubation in the presence or absence of 20ng/ml of IL-7. D1 cells protein extracts were collected 
after 4 hours of IL-7 withdrawal. Then total SPHK, SPHK1 and SPHK2 activities were measured with 
specific buffers by commercially available kinase activity assay. Statistical analysis was performed using 1-
Way ANOVA from duplicates, p = 0.0393 in TAIL7 cells. In D1 cells was performed a t-Test from duplicate 
values, p = 0.0305 for SPHK1 conditions and p = 0.0042 between SPHK2 conditions. 
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4.2. Sphingosine Kinase inhibition effect in IL-7 mediated-signaling 
To determine the role of SPHK in IL-7-mediated signaling in normal and T-ALL 
cells, we used different cell lines. In particular, D1 (‘normal’, non-tumorigenic thymocyte 
IL-7-dependent murine cells), TAIL7 (T-ALL cells, IL-7-dependent) and DND-4.1 (T-
ALL cells, IL-7Rα mutant) were treated with the pan-SPHK inhibitor SKI-II. D1 and 
TAIL7 cells were starved to potentiate the responsiveness to IL-7 and then treated with 
SKI-II. The inhibitor blocked IL-7-mediated upregulation of STAT5, AKT and S6 
phosphorylation without affecting total protein levels (Figure 5A). These effects on IL-7-
mediated signaling were present in both normal and T-ALL contexts, i.e. in D1 and 
TAIL7 cells, respectively (Figure 5A).  
To determine the impact of SPHK inhibition on IL-7Rα gain-of-function mutations, 
we used the DND-4.1 cell line, which has a heterozygous 12 nucleotide insertion in the 
IL-7R gene (IL7R p.L242_L243insLSRC).This alteration is similar to the mutations that 
were described in 10% of T-ALL patients, which promote constitutive activation of IL-
7R without IL-7 requirement. Western blot analysis of DND-4.1 cells corroborated the 
constitutive phosphorylation of IL-7R downstream targets, such as STAT5 and AKT 
(Figure 5A). SKI-II treatment significantly downregulated STAT5 and AKT 
phosphorylation levels and had a perceptible, although minor, effect on S6 
phosphorylation (Figure 5A). 
In order to identify the proximal targets of SPHK in IL-7 signaling, we next 
conducted a time course experiment with SKI-II pre-incubation for two hours with 
subsequent IL-7 stimulation. The early responses to IL-7 stimulation in the presence of 
SPHK inhibition were analysed by western blot. Our data demonstrate that SPHK 
activity is required for very early STAT5 and JAK-1 phosphorylation (30 seconds post-
stimulation), as well as for JAK3 early phosphorylation (1 minute after IL-7 stimulation) 
(Figure 5B). Phosphorylation of downstream effectors, such as AKT and S6, was also 
affected. In contrast, PTEN phosphorylation, which is not IL-7-dependent, was not 
affected by SKI-II (Figure 5B). 
These data suggest that somehow SPHK activity is required for optimal triggering 
of IL-7-mediated signaling in both normal and pathological contexts. 
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Figure 5: SKI-II decreases STAT5, AKT and S6 phosphorylation in IL-7 mediated signaling. (A) D1 
cells were starved for 2h and total protein extracts were collected after 2h incubation with 10µM of SPHK1 
specific inhibitor and 15 min in the presence of 50 ng/ml of IL-7. TAIL7 cells were starved for 24h and total 
protein extracts were collected after 2h incubation with 10µM of SPHK1 specific inhibitor and 15 min in the 
presence of 20ng/ml of IL-7. DND-4.1 total protein extracts were collected after 2h incubation in the 
presence/absence of 10µM of SPHK1 specific inhibitor. STAT5, AKT, PTEN and S6 total and 
phosphorylated and Actin were analysed (B) D1 cells were starved for 2h and total protein extracts were 
collected after 2h incubation with SPHK inhibitor or vehicle and in the presence or absence of IL-7 for 30 
seconds; 1, 5, 15 and 30 minutes. JAK3, JAK1, STAT5, AKT, PTEN total and phosphorylated and Actin 
proteins were analysed 
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4.3. Sphingosine Kinase inhibition reduces cell survival via enhancing 
caspase-dependent apoptosis  
Next, we sought to evaluate the functional impact of our molecular observations. 
We found that SPHK inhibition decreases cell survival in normal murine thymocytes (p 
= 0.0003) and human T-ALL cells (p < 0.0001, Figure 6). This effect was dose- (Figure 
6A) and time-dependent (p < 0.0001, Figure 6B). 
To characterize the cell death mechanism triggered by SPHK inhibition, we 
performed annexin V/ 7AAD staining, in order to evaluate whether apoptosis was 
involved. The different cell populations could be identified as follows: viable (7AAD and 
annexin V double-negative), early apoptotic (annexin V positive, 7AAD negative), and 
late apoptotic/necrotic (7AAD and annexin V double-positive) cells. Inhibition of SPHK 
led to an increase in the frequency of early and late apoptotic cells (Figure 7A), both of 
which contribute to increase the percentages of apoptotic cells in D1 (p = 0.0265), 
TAIL7 (p < 0.0001) and DND-4.1 (p = 0.0005, Figure 7B). The process of apoptosis or 
programmed cell death (PCD) can also be defined by caspase-3 and PARP cleavage. 
In accordance with the annexin V/ 7AAD flow cytometry data, western blot analysis of 
DND-4.1 cells after 24h of SKI-II treatment showed increased cleavage of both 
caspase 3 and PARP (Figure 7C).  
Mitochondrial membrane potential was described as an important parameter of 
mitochondrial function used as a very early indicator of apoptosis. The collapse of the 
mitochondrial transmembrane potential occurs at the same time of the opening of 
mitochondrial permeability transition pores, promoting cytochrome c release, which 
enhances other downstream events in the apoptotic cascade. As expected, SKI-II 
decreased mitochondrial membrane potential in D1 (p = 0.0427), TAIL7 (p = 0.0449) 
and DND-4.1 (p = 0.0002) cells (Figure 8). 
Taken together, these results strongly indicate that SPHK activity is required for 
IL-7 mediated survival of T-ALL cells and murine thymocytes.  
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Figure 6: Sphingosine Kinase inhibition reduces cell survival in normal and T-ALL cells. (A) D1 and 
DND-4.1 cell viability was evaluated in the presence or absence of different concentrations (1, 2.5, 5 µM) 
of SKI-II. TAIL7 cell viability was evaluated in the presence or absence of different concentrations (0.1, 1, 
5, 10 µM) of SKI-II. D1 and TAIL7 cells were cultured with 50 and 20ng/ml of IL-7, respectively. Data 
shown were obtained between 48h (D1 and DND-4.1) and 72h (TAIL7). Viability was obtained by flow 
cytometry with FSCxSSC analysis and normalized to medium conditions. Statistical analysis was 
performed using 2-Way ANOVA from duplicates of two experiments, p = 0.0003 and p < 0.0001. (B) D1, 
TAIL7 and DND-4.1 cell viability was evaluated in the presence or absence of different concentrations 
(5µM) of SKI-II. D1 and TAIL7 cells were cultured with 50 and 20ng/ml of IL-7, respectively. Viability was 
obtained by flow cytometry with FSCxSSC analysis and normalized to IL-7 condition in D1 and TAIL7 cell 
lines, and to medium condition in DND-4.1. Statistical analysis was performed using 2-Way ANOVA from 
duplicates of two experiments, p < 0.0001. 
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Figure 7: Sphingosine Kinase inhibition reduces cell survival by enhancing caspase dependent cell 
apoptosis. (A, B) Cells were cultured in the presence or absence of SKI-II (2.5 and 5µM). D1 and TAIL7 
cells were cultured with 50 and 20ng/ml of IL-7, respectively. AnnexinV/7AAD staining assessed apoptotic 
and viable cells. Data shown was obtained between 48h (D1 and DND-4.1) and 72h (TAIL7). (B) 
Percentages of apoptotic cells were normalized to medium condition. Statistical analysis of D1 and TAIL7 
cell lines were performed using 2-Way ANOVA from duplicates of two experiments, p = 0.00265 and p < 
0.0001, respectively. Statistically significant differences of DND-4.1 were obtained through 1-Way ANOVA 
from duplicates of two experiments, p = 0.0005 is shown. (C) DND-4.1 total protein extracts were collected 
after 24h incubation in the presence/absence of 10µM of SPHK1 specific inhibitor. PARP and caspase-3 
cleavage was analysed. 
	   
THE ROLE OF SPHINGOSINE KINASE 1 IN IL-7-MEDIATED SIGNALING AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA 
	   34	  
 
Figure 8: Sphingosine Kinase inhibition reduces Mitochondrial Membrane Potential. (A, B) Cells 
were cultured in the presence or absence of SKI-II (2.5 and 5µM). D1 and TAIL7 cells were cultured with 
50 and 20ng/ml of IL-7, respectively. Mitochondrial Membrane Potential was assessed by TMRE staining. 
Data shown were obtained between 48h (D1 and DND-4.1) and 72h (TAIL7). (A) Geometric Mean of 
Mitochondrial Membrane Potential cells was normalized to medium condition. Statistically significant 
differences were obtained through 1-Way ANOVA from duplicates of two experiments, p < 0.05 is shown. 
(B) Representative histograms of Mitochondrial Membrane Potential measurement are shown. Mean 
Fluorescence Intensity (MFI) from each condition is shown. 
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4.4. Sphingosine Kinase inhibition prevents cell cycle progression 
and reduces cell proliferation 
Since IL-7 has been shown to promote not only viability but also cell cycle 
progression of T-ALL cells, the effects of SKI-II on cell cycle and proliferation after IL-7 
stimulation were also measured. SKI-II treatment decreased cell proliferation of IL-7-
cultered TAIL7 cells (p = 0.0002) and DND-4.1 cells (p = 0.0189, Figure 9A). The same 
results were obtained for D1 cell line (data not shown). Regarding the effects on cell 
cycle, SKI-II led to a cell cycle arrest in G0/G1 in TAIL7 and DND-4.1 cell lines (Figure 
9B). Similar results were obtained for D1 cell line (data not shown). 
These results indicate that SPHK activity is essential for IL-7-mediated cell cycle 
progression and proliferation.  
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Figure 9: Sphingosine Kinase inhibition supresses cell proliferation and induces cell cycle 
blockage in T-ALL. (A, B) Cells were cultured in the presence or absence of SKI-II (2.5 and 5µM). TAIL7 
cells were cultured with 20ng/ml of IL-7. (A) Data shown were obtained between 48h (DND-4.1) and 72h 
(TAIL7). Thymidine incorporation values were normalized to medium condition. Statistical analysis of 
TAIL7 and DND-4.1 cell lines were performed using 1-Way ANOVA from duplicates of two experiments, p 
= 0.0002 and p = 0.0189, respectively is shown. (B) Data shown were obtained between 24h (DND-4.1) 
and 48h (TAIL7). Cell cycle phase percentages were evaluated by flow cytometry analysis of PI staining in 
ethanol-fixed and permeabilized cells. 
 
 
4.5. Sphingosine Kinase inhibition decreases cell size and transferrin 
receptor expression  
IL-7 was shown to promote cell size increase (cell growth), which associates with 
increased metabolism and expression of ‘activation’ markers such as the transferring 
receptor CD71. Inhibition of SPHK impaired IL-7-mediated TAIL7 cell growth cells (p = 
0.0109) and promoted the atrophy of DND-4.1 cells (p = 0.0016, Figure 10A). 
Surprisingly, in contrast to T-ALL cells, SKI-II treatment increased the cell size of D1 
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murine thymocytes (p = 0.0041, Figure 10A). In accordance, we found that SPHK 
inhibition was negatively affected CD71 expression in both TAIL7 (p = 0.0324) and 
DND-4.1 cells (p < 0.0001, Figure 10B). In agreement with the cell size response, 
CD71 was also more expressed after SKI-II treatment in D1 cells (p = 0.0025, Figure 
10B). 
These results suggest that SPHK inhibition decreases cell size and transferrin 
receptor expression selectively in T-ALL cells.  
 
 
 
Figure 10: Sphingosine Kinase inhibition decreases cell size and transferrin receptor expression. 
(A, B) Cells were cultured in the presence or absence of SKI-II (2.5 and 5µM). TAIL7 cells were cultured 
with 20ng/ml of IL-7. Data shown were obtained between 48h (D1 and DND-4.1) and 72h (TAIL7). (A) Cell 
size was obtained by flow cytometry with FSCxSSC analysis.  TAIL7 and DND-4.1 were normalized to 
medium conditions. D1 values were normalized to IL-7 condition, due to the lower % of viable cells in 
medium condition, we were not able to measure cell size (n.d. - no data). Statistical analysis was 
performed using 1-Way ANOVA from a representative experiment, p = 0.0041, p = 0.0109 and p = 0.0016, 
respectively. (B) Transferrin receptor (CD71) expression was evaluated by specific antibody staining and 
analyzed by flow cytometry. TAIL7 and DND-4.1 were normalized to medium condition. D1 values were 
normalized to IL-7 condition, due to the lower % of viable cells in medium condition, we were not able to 
measure CD71 (n.d. - no data). Statistical analysis was performed using 1-Way ANOVA from a 
representative experiment, p = 0.0025, p = 0.0324 and p < 0.0001, respectively. 
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DISCUSSION 
 
The critical role of SPHKs in the development of a wide range of tumors has been 
exhaustively demonstrated, including in breast, lung, ovary, stomach, uterus, and 
kidney cancers, and both chronic and acute myeloid leukemias (99, 100). It is well-
known that SPHK1 expression or/and activity are increased in cancer cells, being 
related with cell survival and proliferation (79). In contrast, SPHK2 function is still 
controversial, apparently displaying two contrasting functions under different 
conditions. In mouse embryonic kidney cells (HEK293) or mouse embryonic fibroblasts, 
SPHK2 silencing with small interfering RNA (siRNA) prevented the induction of 
apoptosis (121). In opposition, in human breast cancer cells, SPHK2 knockdown 
inhibited the growth of xenografted tumours (113). SPHKs subcellular localization has 
been pointed out as the decisive factor, nonetheless additional experiments are 
required (76).  
Recent studies have established the importance of SPHKs in hematological 
malignancies. In Multiple Myeloma (MM), IL-6 stimulation leads to increased SPHK1 
expression and activity, which upregulates myeloid cell leukaemia (Mcl-1), increasing 
cell proliferation and survival (106). Recently, it has been demonstrated that SPHK2 
activity, but not its expression, was higher in ALL samples than normal B-cell 
progenitors (116). In this work, we show that SPHK1, but not SPHK2, may have an 
important role in T-ALL pathology since it is significantly overexpressed in malignant 
samples. In agreement with this notion, it has been shown that SPHK inhibition 
promotes apoptosis of human T-ALL Jurkat cells (110), suggesting that SPHK 
overexpression in T-ALL cells is of functional relevance. 
SPHK has been indicated as a cytokine-activated kinase. As stated in the 
previous paragraph, IL-6 stimulates SPHK1 activity and leads to a decrease in both 
sphingosine and ceramide levels, which leads to suppression of cell apoptosis in MM 
(106). Furthermore, ERK1/2 and PI3K/mTOR are the main players responsible for 
SPHK1 phosphorylation and activation (106). Constitutive activation of IL-7 pathway, 
which drives the activation of JAK/STAT and both of these pathways (63), has been 
associated with leukemogenesis in T-ALL. In that sense, IL-7 signaling emerges as an 
obvious candidate for SPHK activation, and in fact we demonstrated that IL-7 
stimulation leads to increased activity of both SPHK1 and SPHK2. It remains, however, 
to be understood what is the functional role of each of the two kinases in the context of 
IL-7-mediated signaling. 
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Previously, it has been reported that SPHK translocation from the cytosol to the 
plasma membrane is absolutely required for SPHK activation. These data suggest that 
plasma membrane localization is essential not only for SPHK activation, thus placing 
SPHK in close proximity to its substrate, sphingosine, but also to facilitate its product, 
S1P, acting on intracellular signaling targets or moving to the extracellular 
compartment and stimulating its G protein-coupled receptors (88). Here, we 
demonstrated for the first time that SPHK has a critical role in IL-7 and IL-7R-mediated 
signaling, and is absolutely required for the activation of downstream elements in IL-7 
signaling pathways in normal T-cell precursors and T-ALL cells. Before, it was 
proposed that IL-7Rα association with clathrin and subsequent internalization is 
necessary for optimal IL-7-mediated signal transduction (122). The time-course 
experiments we now conducted showed that SPHK inhibition has an early effect on IL-
7 signaling, which could indicate that SPHK is placed very upstream, at close proximity 
to the JAKs and PI3K - possibly even physically interacting with them or with the IL-7R. 
Alternatively, SPHK inhibition may promote changes in lipid membrane composition 
and by this way decrease IL-7 internalization, compromising IL-7-mediated signaling. 
Further experiments are required to clarify if and what are the molecular mechanisms 
by which SPHK may affect IL-7R internalization. On the other hand, SKI-II inhibits the 
conversion of sphingosine and ceramide into S1P, promoting intracellular accumulation 
of ceramide and sphingosine. This elevation of ceramide activates serine/threonine 
protein phosphatases PP1 and PP2A that dephosphorylate Akt (120). Akt deactivation 
is mediated not only by IL-7 signaling shutdown but also by increased ceramide, which 
could explain the effect of SKI-II in the regulation of PI3K/AKT pathway activation. This, 
however, would not justify the impact on JAK/STAT pathway. 
Importantly, in agreement with its effects on key survival pathways, we further 
demonstrate that in T-ALL and normal thymocytes, SPHK is absolutely required for IL-
7-mediated pro-survival effects. Previously it was demonstrated that IL-7 induces the 
phosphorylation of Akt, which interacts with its downstream targets GSK-3, FOXO1, 
and FOXO3a in a PI3K-dependent manner, leading to their inactivation and nuclear 
export, which promote cell viability. In addition, GSK-3 can also phosphorylate and 
inhibit NF-ATc, a transcription factor involved in proliferation and Bcl-2 gene 
transcription (63). It was also well shown that sphingosine rheostat is responsible for 
apoptosis regulation. Death-inducing signals reach the mitochondria, promoting 
cytocrome c (cyt c), adaptor of protein Apaf-1, and precursor of caspase-9, Smac 
diablo and dATP release. Pro-caspase 9 is cleaved and activates other caspases, such 
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as caspase-3, -6 or -7, which lead to apoptosis. Some reports indicate that increased 
levels of ceramide are responsible for mediating Fas- and TNF-α-induced apoptosis 
and precede previously described mitochondrial events in different stress conditions. 
S1P has an opposite effect, inhibiting cyt c and Smac/Diablo translocation to the 
cytoplasm, thereby preventing apoptosis. These findings suggest that a combination of 
both conditions, decreased S1P formation and increased ceramide levels, will promote 
cell apoptosis, which is achieved through SPHK inhibition (110). Our data is consistent 
with these reports, since SKI-II induced mitochondrial transmembrane potential loss, 
caspase-3 and PARP cleavage, and consequent apoptosis of malignant as well as 
normal T-cell precursors. Of note, mitochondrial transmembrane potential loss has 
been observed during ceramide-induced effector phase of apoptosis.  
In non-transformed NIH 3T3 fibroblasts, sphingosine kinase transfection 
significantly increases the proliferative rate of fibroblasts (123). Our data demonstrated 
that SPHK inhibition decreases the proportion of cells in S-phase and blocks the G1/S 
transition in IL-7 stimulated normal and T-ALL cells. This could be explained possibly 
by the negative effect of SKI-II on proliferative signals, such as Cyclin-dependent 
Kinase (Cdc2 and Cdk2 kinases) expression, which can also be regulated by IL-7-
mediated signaling (22). GSK-3β, which is inactivated by phosphorylation by Akt, is 
described as responsible for cyclin D1 regulation, contributing to cell cycle arrest. Since 
SPHK inhibition represses the activation of IL-7-mediated pathways, cell cycle related 
molecules are also expected to be repressed, explaining potentially the effect seen in 
T-ALL cells and normal T-cells after SPHK inhibition. 
There are evidences that suggest a relation between increased cell size, cell 
metabolism and oncogenesis. TFR1 (CD71) is upregulated in order to supply increased 
cell metabolism requirements. Previously it was shown that IL-7 contributes to T-ALL 
cell growth and metabolic activation, increasing cell size and surface expression of 
CD71. Those events are dependent on PI3K/Akt activation (63). Recently, Pham et al. 
showed that SPHK1 expression leads to increase of CD71 surface levels and 
transferrin uptake in a manner that appears to be dependent also on c-Myc (124). We 
showed that SKI-II decreases CD71 expression and cell size in T-ALL cells. It remains 
to be determined if this effect is dependent on SPHK1-mediated activation of PI3K 
pathway. Surprisingly, SPHK inhibition upregulated CD71 surface expression and cell 
size in normal thymocytes, represented by the mouse D1 cell line. It is possible that 
normal T-cell precursors differ from T-ALL cells in IL-7-mediated, SPHK-dependent 
regulation of metabolism - an observation that may be of therapeutic importance. It 
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should be noted, nonetheless, that experiments involving primary human thymocytes 
are required to confirm the data obtained so far with D1 cells.  
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CONCLUSION 
IL-7 and its receptor are crucially involved in T-cell leukemia pathophysiology. 
The current study provides evidence that IL-7/IL-7R-mediated signaling upregulates 
SPHK1 kinase activity and absolutely requires SPHK for full activation of downstream 
effectors. The activation of IL-7 pathway is not only related with increased viability, but 
also involved in the regulation of cell size and proliferation. Altogether, our results 
indicate that SPHK plays an important role in IL-7-mediated signaling and its 
downstream effects on T-ALL cells. Together with our evidence that SPHK1 is 
overexpressed in T-ALL cells, these findings could constitute a solid argument for the 
further deepening of the understanding of the role of SPHK in T-ALL, which could help 
define whether SPHK is a valid molecular target for therapeutic intervention in T-ALL. 
To complement our in vitro studies, analysis of inhibition of SPHK in primary T-ALL 
samples should be performed and in vivo efficacy of inhibitors of SPHK for the 
treatment of T-ALL should be tested.  
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